TABLE 1.
Studies of HBV reactivation in HCV-positive individuals treated with DAAs
| Reference | Sample Size (Number with Reactivation) | Country | DAA Regimen |
|---|---|---|---|
| Case reports | |||
| 36 | 2(2) | United States | Sofosbuvir + simeprevir |
| 37 | 1(1) | France | Sofosbuvir + ledipasvir |
| 38 | 1(1) | United States | Sofosbuvir + simeprevir + ribavirin |
| 18 | 1 (1) | Italy | Sofosbuvir + ledipasvir |
| 39 | 1 (1) | Japan | Daclatasvir + asunaprevir |
| 40 | 1 (1) | Japan | Simeprevir + PEG-IFN + ribavirin |
| 41 | 1 (1) | Japan | Daclatasvir + asunaprevir |
| 42 | 1 (1) | Japan | Daclatasvir + asunaprevir |
| Cohort studies | |||
| 43 | 64 (4) | Taiwan | Multiple IFN-free regimens |
| 44 | 84(5) | Japan | Multiple IFN-free regimens |
| 45 | 103 (0) | Taiwan and South Korea | Sofosbuvir + ledipasvir |
| 46 | 183 (4) | Japan | Sofosbuvir + ledipasvir or Sofosbuvir + ribavirin |
| 47 | 327 (3) | China | Multiple IFN-free regimens |
| 48 | 352 (6) | Spain | Multiple IFN-free regimens |
| 49 | 808 (13) | Germany | IFN-based regimens Multiple IFN-free regimens |
| 50 | 62 290 (9) | United States | Multiple IFN-free regimens |
Abbreviations: DAA, direct-acting agents.